<unk>  is a drug used for the treatment of cystic fibrosis (CF) in people six years and older, who have a F508del mutation, the most common type of mutation in the CFTR gene . It is sold as a fixed-dose combination with ivacaftor under the brand name Symdeko. It was approved by the U.S. FDA in 2018. The combination of elexacaftor,<unk> , and ivacaftor is being sold as Trikafta. In 2019, the U.S. Food and Drug Administration (FDA) approved a combination of elexacaftor,<unk> , and ivacaftor.
Tezacaftor
Enarodustat
Vagisil
Sesquimustard
Pretomanid
Androvax
Crofelemer
Clinatec